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osting by EAbstract A novel sensitive ﬂuorimetric method was investigated for the assay of fexofenadine
hydrochloride (FEX) using silver nanoparticles (NPs) as a ﬂuorescence probe. The NPs, which were
prepared by chemical reduction of silver nitrate with sodium borohydride (reducing agent) in aque-
ous solution (without organic stabilizers) were water soluble, stable and had narrow emission band.
The addition of drug to NPs solution caused considerable quenching of the emission band of silver
NPs, which was likely due to the complexation of the drug to silver NPs. Under the optimum con-
ditions, the quenched ﬂuorescence (FL) intensity was linear with the concentration of FEX in the
range of 1 · 107 to 2.5 · 105 mol L1 (0.9985) with a detection limit of 1.2 · 108 mol L1. The
quenching mechanism of the studied drug on the emission band of silver NPs was explained by
Stern–Volmer law. The developed method was applied to FEX determination in a pharmaceutical
formulation (allegra tablets) and biological ﬂuids (human serum and urine).
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lsevier1. Introduction
Fexofenadine ((±)-2-[4-[1-hydroxy-4-[4-(hydroxydipheny-
lmethyl) piperidino] butyl] phenyl]-2-methylpropanoic acid
(Fig. 1a) (FEX)) is an oral, second generation antihistamine
drug, which is used for the treatment of seasonal allergic rhini-
tis and chronic urticaria. The attachment of histamine to the
receptors causes the activation of cell to release chemicals,
which produce allergy effects, e.g., sneezing. FEX blocks one
type of receptor (the H1 receptor) for non-sedating histamine
and thus prevents activation of non-sedating histamine recep-
tor-containing cells by histamine (Bharathi et al., 2008).
Figure 1 Chemical structures of (a) FEX and (b) fexofenadine hydrochloride.
252 Z.A. Alothman et al.FEX and other second-generation antihistamines, unlike
the ﬁrst-generation antihistamines do not readily enter the
brain from the blood, hence causing less drowsiness. The co-
administration of FEX with erythromycin or ketoconazole re-
sults in signiﬁcant increase of plasma concentrations of the H1-
antagonist (Simpson and Jarvis, 2000; Simons and Simon,
1999). FEX is also cardiotoxic, because it does not block the
potassium channel involved in repolarization of cardiac cells.
A number of bio-analytical methods (with FL detection)
have been reported for the determination of FEX in recent
years, which showed improved sensitivity compared to conven-
tional methods (Uno et al., 2004; Coutant et al., 1991; Sura-
paneni and Khalil, 1994). These include; high-performance
liquid chromatography (HPLC) (Coutant et al., 1991; Sura-
paneni and Khalil, 1994), HPLC with electrospray mass spec-
trometry (MS) (Adams et al., 1997; Lalonde et al., 1996) and
HPLC coupled with mass spectrometric detection, etc. How-
ever the long chromatographic elution time, consumption of
large sample, laboratories specialties (human resources) and
high cost equipments (Fu et al., 2004; Hofmann et al., 2002)
have made these methods un-suitable for pre-clinical pharma-
cokinetic studies.
Fluorimetric techniques are becoming increasingly impor-
tant for quantitative determination of pharmaceutical drugs
(Karim and Lee, 2008; Karim et al., 2007; Karim et al.,
2006) due to their high sensitivity, short run time, cheap instru-
mentation and selectivity, etc. The recent use of luminescent
NPs (ZnS, ZnSe, CdS, CdTe and CdSe) revolutionalized ana-
lytical techniques for drug determination due to their unique
properties, which originates from their quantum size effect,
brightness, strong stability against photo bleaching and resis-
tance to blinking (Wang et al., 2002). They have been investi-
gated extensively for various potential applications including
FL biological labels, photovoltaic cells, light-emitting diodes
and optical sensors, etc.
However, pristine metal NPs has limited application as a
ﬂuorescent in the determination of drug, bio-chemical probes
and sensors due to their aggregation in aqueous solutions,
complicated surface modiﬁcation procedures and reduced bio-
compatibility. Among the noble metal NPs, silver NPs have at-
tracted more attention (Ghosh et al., 1996; Nersisyan et al.,
2003; Rabin et al., 2000; Geddes et al., 2003; Jiang et al.,
2005; Maali et al., 2003; Evanoff and Chumanov, 2004) for
their advantages due to their biocompatibility, photosensitive
components (Hailstone, 1995), catalysts (Shiraishi and Toshi-ma, 1999; Sclafani et al., 1991; Tada et al., 2000) and sur-
face-enhanced Raman spectroscopy (Shirtcliffe et al., 1999;
Bright et al., 1998) for the determination of drugs.
In the present work, an attempt is made to prepare ﬂuori-
metric silver NPs in aqueous solution via chemical reduction
of silver nitrate with sodium borohydride without using organ-
ic stabilizers (Darya et al., 2007). The applicability of the pre-
pared silver NPs was evaluated in the development of a more
precise, relatively short run time and reliable method for the
determination of FEX in pharmaceutical formulations (allegra
tablets) and biological ﬂuids (human serum and urine). We be-
lieve this novel method could ﬁnd efﬁcient use in the pre-clin-
ical pharmacokinetic studies of FEX and related drugs.
2. Experimental
2.1. Materials
All reagents were of analytical grade and were used without
further puriﬁcation. FEX, silver nitrate (99.8%), sodium boro-
hydride (98%) were purchased from Fluka (Germany). Com-
mercially available pharmaceutical drug (allegra tablets) was
purchased from local medical store. The standard solutions
of FEX were prepared in water daily. Deionized (DI) water
was used throughout the experiments.
2.2. Pharmaceutical sample solution preparation
The average weight of ten allegra tablets (Roche South Korea)
containing 60 mg of FEX was taken and ﬁnely powdered by
pestle in a mortar. The sample amount required for
1 · 104 mol L1 of FEX was transferred to 25 mL volumetric
ﬂask and was dissolved in DI water. The contents of the ﬂask
were sonicated for 5 min to affect complete dissolution. The
sample solution was ﬁltered and suitable aliquot of the clear
ﬁltrate was collected and stored in the refrigerator for further
use.
2.3. Apparatus
All the spectroﬂuorimetric measurements were carried out with
a SPEX Fluorolog-2 Spectroﬂuorometer. A 450-W xenon
lamp was used as the excitation light source for the spectrom-
eter and R 928 photomultiplier tube powered at 950 V (Ham-
Scheme 1 Schematic for the preparation of silver NPs.
Figure 2 (I) TEM image of silver NPs and 2(II) absorbance
spectra of silver NPs. Conditions: Silver NPs 1 · 104 M, 2 · 104
M, 3 · 104M, 4 · 104M.
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Figure 3 Effect of NPs concentration on the FL intensity.
Conditions: FEX 1.5 · 105 M.
Spectroﬂuorimetric determination of fexofenadine hydrochloride in pharmaceutical preparation 253amatsu Co.) was used as a detector. Excitation and emission
monochromator slit, increment, and integration time were set
at 1.25 mm, 1 nm and 1 second, respectively. All spectral data
were obtained by SPEX DM 3000F spectroscopy computer.
2.4. Basic procedure
In this paper the synthesis of silver NPs (Scheme 1) in aqueous
solution was carried out via chemical reduction of silver nitrate
using sodium borohydride without using organic stabilizers
(Darya et al., 2007). The synthesis was carried out in 0.5 and
1 L ﬂasks pre-washed with concentrated nitric acid. The
remaining acid on the glass walls of the ﬂasks was removed
by rinsing the ﬂasks with sufﬁcient amounts of DI water.
AgNO3 solution (1 mmol L
1) was taken into the syringe
and mixed to the fresh, ice-cold sodium borohydride solution
in 1:3 (1 mmol L1 AgNO3:1 mmol L
1 NaBH4) ratio under
vigorous stirring. During mixing, the mixture turned bright
yellow within ﬁrst 20 second, stirring was stopped immediately
after the completion of injection (not more than 2 min) of sil-
ver nitrate solution. The ﬁnal color of silver NPs was brown-
ish-dark-yellow. The reaction mixture was kept in darkness
to avoid the inﬂuence of daylight.
The NPs were mono-dispersible and stable at 5 C for one
month. The NPs were used as the ﬂuorimetric probes for the
determination of FEX. The following procedure was adopted.
To a 4 mL FL cell, appropriate volumes of NPs and FEX were
added. The mixture was diluted to the volume with DI water
and mixed before the FL intensity was measured. The excita-
tion wavelength was set at 391 nm and the emission wave-
length at 540 nm.
3. Results and discussions
3.1. TEM images and UV spectral characteristics
TEM image shows the dark spherical shaped, mono-dispersed
silver NPs with an average size of 18 nm (Fig. 2I), which was
smaller compared to the NPs (with an average size 23 nm),
reported by Darya et al. (2007). The narrow absorption peak
Table 1 The determination of FEX in tablets and recoveries
from spiked tablets, serum and urine samples.
254 Z.A. Alothman et al.near 400 nm (Riboh et al., 2003; Malinsky et al., 2001) in the
UV–vis spectrum (Fig. 2II) of the prepared silver NPs corre-
sponds to the characteristic wavelength of silver absorbance.
This narrow absorption peak, also conﬁrms the high level of
mono-dispersity of the silver NPs.
3.2. Optimization of silver nanoparticles (NPs) concentration
The concentration of silver NPs greatly inﬂuenced the FL
intensity of the studied system (Fig. 3). The FL intensity in-
creased and reached to the maximum value, when the concen-
tration of nanoparticles was in the range of 4.0 · 105–
6.0 · 105 mol L1. Further increase of concentration resulted
in the decrease of the FL intensity. Considering the sensitivity
and linear range, 6.0 · 105 mol L1 was recommended as the
optimum concentration of NPs.
3.3. Fluorescence (FL) spectral characteristics
Fig. 4 shows the emission spectra of silver NPs in the absence
and presence of various concentrations of FEX. Silver NPs
have shown characteristic emission at 541 nm with excitation
at 391 nm. It was observed from the experimental results that
the FL intensity of the silver NPs was quenched without any
shift, when FEX was added to the system. This quenching
might be due to the formation of non-ﬂuorescent ground state
complex between the ﬂuorophore and the quencher. The non-
ﬂuorescent complex absorbs light and immediately returns to
the ground state without emission of photons, as a result only
the un-complexed ﬂuorophore give FL emission, hence
quenching the total FL intensity.
3.3.1. Fexofenadine (FEX) quenching of silver nanoparticles
(NPs)
The effect of quenching can be described by the stern–volmer
law (Stern and Volmer, 1919):
ðf0=fÞ  1 ¼ KCQ
Where f0 is the FL intensity in the absence of the quencher
FEX, f is the FL intensity at concentration Q of the quencher
FEX and K is the proportionality constant. If a system follows520 530 540 550 560 570 580
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Figure 4 FL emission spectra (excitation at 391 nm) of silver
NPs at 541 nm in the absence (a) and in the presence (b, c, d) of
FEX. Conditions: FEX (b) 1.5 · 106, (c) 3.3 · 106 and (d)
1.6 · 105 M; (a) Silver NPs 6 · 105 M.the law, a plot of f0/f versus CQ yields an intercept of one on
the y-axis and a slope equal to K. The f0/f term linearly in-
creased with increase in the FEX amount.
The effect of static quenching with respect to temperature
was lower at higher temperature. Dynamic quenching depends
on diffusion. Since higher temperature results in larger diffu-
sion coefﬁcients, the quenching constants are expected to in-
crease with increasing temperature. Therefore it can be
concluded that the quenching mechanism is static and quench-
ing by FEX is due to the formation of a non-ﬂuorescent com-
plex between silver NPs and FEX.
3.4. Analytical performance
3.4.1. Calibration curve
Under the optimum experimental conditions, a typical calibra-
tion curve was obtained for the determination of FEX by plot-
ting FL signal versus FEX concentration. The calibration
curve was linear in the range of 1 · 107 to 2.5 · 105 mol L1
(r= 0.9985, n= 5), and the detection limit, deﬁned as three
times the S.D for the reagent blank signal, was
1.2 · 108 mol L1 FEX.
3.4.2. Determination of FEX in pharmaceutical preparation
The validity of the proposed FL techniques for the determina-
tion of FEX in pharmaceutical preparation was investigated.
After sample preparation and adequate dilution the method
was applied to the direct determination of FEX in allegra tab-
lets using calibration curve. The summarized results for the
analysis of allegra tablets are shown in Table 1. The results
showed that the proposed method could be applied success-
fully for the determination of FEX in pharmaceutical
preparation.
The mean results for ﬁve determinations of FEX were very
close to the declared value on the label. To check the accuracy
of the method and to know whether the excipients in tablet
show any interference with the analysis, the recovery studies
were performed. Recovery studies were carried out after theSamples Fexofenadine
Allegra tablets
Labeled claim/tab (mg) 60
Amount found/tab (mg) 60.24 ± 0.80
Average amount/tab (%) 100.40
Added amount (lM) 50 (n= 5)
Recovered amount (lM) 49.77
Average recovered (%) 99.54
R.S.D (%) 0.57
Serum sample
Added amount (mM) 0.5 (n= 5)
Recovered amount (mM) 0.514
Average recovered (%) 102.8
R.S.D (%) 2.33
Urine sample
Added amount (mM) 0.5 (n= 5)
Recovered amount (mM) 0.512
Average recovered (%) 102.4
R.S.D (%) 1.24
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lyzed formulation of FEX. The results indicated the absence
of interference from commonly encountered pharmaceutical
excipients used in the selected formulation (Table 1).
3.4.3. Determination of FEX in spiked serum sample
In order to check, the possibility of applying the FL technique
to the human serum samples, the proposed method was ap-
plied to the determination of FEX in spiked serum sample.
Proteins and endogenous substances were removed from the
serum samples via precipitation by the addition of acetonitrile
and centrifugation at 4000 rpm. The supernatants were then
taken and diluted with DI water. Stability of the fortiﬁed ser-
um samples was tested by making ﬁve consecutive analyses of
the sample over a period of approximately 24 h.
No signiﬁcant changes were observed in the peak currents
and potentials between the ﬁrst and last measurements. The
serum sample with standard FEX was spiked by FEX to con-
ﬁrm the peak position and corresponding FL response for the
added concentration. Linear response was observed by adding
FEX to the previously fortiﬁed serum sample, which conﬁrmed
the applicability of the proposed method to human serum. The
recovery results are given in the Table 1.
3.4.4. Determination of FEX in urine sample
The applicability of the studied method for the determination
of FEX in spiked urine was investigated. The direct determina-
tion of FEX in urine was found to be possible by employing a
high dilution of the sample. The experiment was performed for
urine samples with ﬁve replicates for each sample. The results
are given in Table 1. From the recovery data it was observed
that FEX can be determined in urine matrix with reliable
results.
4. Conclusion
The novel ﬂuorimetric method for the determination of FEX
based on the FL quenching of silver NPs has advantages in
the simplicity, rapidity and sensitivity. The method has shown
good linearity over the range of 1 · 107 to
2.5 · 105 mol L1. (r= 0.9985) with a detection limit of
1.2 · 108 mol L1. The developed method was successfully
applied for the determination of FEX using silver NPs as FL
probe in human serum and urine sample. The experimental re-
sults suggested that silver NPs may provide a new class of ﬂuo-
rophore for use in chemical sensing and biomedical
applications.References
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